ArticleFrontiers in immunology2026
Comparative systemic pathogenicity and host tropism of ancestral SARS-CoV-2, Delta, and Omicron EG.5 variants in K18-hACE2 mice.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: SARS-CoV-2 undergoes persistent genomic evolution, yet prevalent circulating variants tend to evolve toward reduced pathogenicity. However, direct comparative pathogenesis data involving contemporary, immune-evasive strains-such as the Omicron EG.5 subvariant (a descendant of the globally dominant XBB lineage)-relative to ancestral strains remain scarce. Methods: To clarify the evolutionary trajectory of viral virulence, we conducted a systematic, head-to-head comparison of the in vivo pathogenicity of three pivotal strains: the ancestral Wild-type (Wuhan lineage), Delta, and the currently circulating Omicron EG.5. We utilized the highly susceptible K18-hACE2 transgenic mouse model to assess disease progression, viral burden, and histopathology. Results: Despite uniformly progressing to lethality in this model, the strains exhibited a distinct gradient in the kinetics and severity of disease. The Wild-type strain demonstrated the most rapid disease progression, highest viral loads across multiple organs (notably liver, brain, lung, and intestine), and most severe histopathological damage. The Delta variant showed an intermediate phenotype. Strikingly, the Omicron EG.5 variant displayed significantly attenuated pathogenicity, characterized by markedly delayed mortality, milder clinical presentation, and reduced tissue viral burden, yet it retained a capacity for multi-organ infection. Discussion: Our study provides direct experimental evidence for a pronounced attenuation in pathogenicity along the evolutionary trajectory from Wild-type through Delta to Omicron EG.5. These findings offer crucial insights for risk assessment of emerging variants and underscore the need for ongoing surveillance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.